Pediatric Neurofibromatosis: What’s Next for the Rare Tumor Syndrome? – Oncology Nursing News

Until recently, there was no FDA-approved therapy for pediatric patients with neurofibromatosis type 1 (NF1), a genetic disorder that causes tumor growth – which could become cancerous – in young children.

On April 10, the FDA approved selumetinib (Koselugo) for children over the age of 2 who have inoperable or symptomatic plexiform (PNs) – tumors on nerve sheaths. NF1-related tumors can drastically impair a patient’s daily function, be incredibly painful, and turn into cancerous tumors as well.

Click here to read full article

Font Resize